FEATURE
Promising Oral Regimens Offer New Hope for Rifampin-Resistant Tuberculosis Treatment
Time to read: 07:10. The endTB Phase 3 clinical trial aimed to find shorter, effective, and safe treatment regimens for rifampin-resistant tuberculosis by using newer drugs like bedaquiline and delamanid, along with repurposed drugs such as clofazimine and linezolid.
Source: NEJM
Feature
Text
Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials
Time to read: 10:57. In this study, researchers of this study, Gao & Guyatt et al. aimed to determine the optimal antiviral drug for the treatment of severe influenza and to support the updated WHO influenza guidelines (September 13, 2024).
Source: The Lancet
Text
Prescribing patterns of echinocandins in adult patients in a private hospital in Gauteng, South Africa
The Candida species group is responsible for a fourth of all hospital-acquired infections. While Candida albicans accounts for the majority of these infectious, the number of patients infected with non-albicans Candidas – such as Candida glabrata, Candida parapsilosis, Candida krusei and Candida tropicalis - is steadily growing. The researchers of this study, Grey et al., sought to determine whether South African doctors comply with the available guidelines.
Source: Southern African Journal of Infectious Diseases,
Text
Candida Auris: priority pathogen on the march
Keywords associated with this article: sepsis, candidemia, candida auris, COVID, infection control, WHO, fungal infection, antimicrobial, multi-drug resistant
Text
